Table 2 The number of deaths in each group and the number of major adverse events
Mortality within 30 days | LVOT obstruction | Stroke | Vascular complication | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
All-cause mortality | Cardiovascular | |||||||||||||
ViV | ViR | ViMAC | ViV | ViR | ViMAC | ViV | ViR | ViMAC | ViV | ViR | ViMAC | ViV | ViR | ViMAC |
3 | 0 | 2 | – | – | – | 3 | 3 | 2 | – | – | – | – | – | – |
20 | 14 | 20 | – | – | – | 7 | 7 | 23 | 7 | 0 | 2 | 5 | 5 | 4 |
9/172 | 5/73 | – | 5/172 | 5/73 | – | 0/172 | 4/73 | – | 3/95 | 1/47 | – | 16/172 | 0/73 | – |
– | 0 | 6 | – | 0 | 4 | – | – | 4 | – | – | 3 | – | 0 | 2 |
47/584 | 12/104 | 20 | 28/584 | 7/104 | – | 5 | 6 | 10 | 7 | 0 | 4 | 20 | 6 | – |
56 | 19 | – | – | – | – | – | – | – | 12 | 1 | – | 49 | 4 | – |
Acute kidney injury | Postprocedural Mitral Regurgitation | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trace/none | 1 (+) | 2 (+) or greater | ||||||||||||
ViV | ViR | ViMAC | ViV | ViR | ViMAC | ViV | ViR | ViMAC | ViV | ViR | ViMAC | |||
– | – | – | – | – | – | – | – | – | – | – | – | |||
14 | 13 | 7 | – | – | – | – | – | – | – | – | – | |||
7/172 | 4/73 | – | 107/145 | 40/67 | – | 30/145 | 19/67 | – | 8/145 | 8/67 | – | |||
– | 0 | 1 | – | – | – | – | – | – | – | – | – | |||
– | – | – | 557 | 63 | 55 | 93 | 44 | 36 | 8 | 3 | 2 | |||
75 | 29 | – | 660 | 113 | – | 171 | 73 | – | 26 | 36 | – | |||